Skip to content

How Clinicians Manage Their Patients Who May Need Antithrombotic Care

How Clinicians Manage Their Patients Who May Need Antithrombotic Care

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05923658
Enrollment
2500
Registered
2023-06-28
Start date
2023-10-01
Completion date
2023-12-01
Last updated
2023-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombosis

Keywords

Clinical Practice Guidelines

Brief summary

This study aims to assess the knowledge and provide an opportunity for education to clinician attendees of the Canadian Cardiovascular Congress (CCC) meeting using a series of simulated patient case scenarios.

Detailed description

Health conditions requiring antithrombotic therapy are highly prevalent in Canada, contributing substantially to healthcare costs and patient quality of life. For example, over 60,000 Canadians will experience a heart attack per year.1 Alarming statistics such as this warrant appropriate treatment approaches from clinicians who specialize in cardiovascular conditions. The CCC is a national conference during which individuals with an interest or expertise in cardiovascular health from across the country attend. Leveraging this unique opportunity by implementing a simple educational endeavour during the 2023 event can provide instrumental insights on the most appropriate treatments recommended from the latest clinical practice guidelines to a wide set of practitioners; this could, in turn, potentially improve patient health outcomes. This endeavour will take place at a set date from October 25th to 29th, 2023. Attendees of the CCC who approach a booth set up by the lead investigator of this project will be presented with the study letter of information and consent form on a tablet (i.e., an iPad). After providing an electronic informed consent to participate, a series of patient case scenarios that require antithrombotic care and therapy will be shown. For each case scenario, the attendee (now, considered a study participant) will be asked to indicate the treatment approach that he/she would choose. And finally, after reviewing all case scenarios and selecting the best treatment approach to his/her knowledge, the participant will be asked to provide an email address (which could be an anonymized one) to send the most appropriate treatment approaches for each case scenario. This last step allows the participant an educational opportunity to learn what the best practice approach is based on the most up-to-date clinical practice guidelines. The approximate total duration of the study is one-hour in total.

Interventions

None listed

Sponsors

Anthony Tang
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years

Inclusion criteria

* Any clinician (i.e., licensed medical doctor, nurse practitioner) attending the CCC's 2023 event from October 25th-29th, 2023 will be included in this endeavour so long as they have the ability to provide informed consent (i.e., can read, write, and understand the English language).

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Adherence to Clinical Practice Guideline Recommendations1-Month.Open-ended recommendations provided by all participants on how they would treat each patient case in each scenario will be qualitatively coded as follows: 1) adhering to the recommendations provided in the guidelines, 2) partly adhering the recommendations provided in the guidelines, and 3) not adhering to the recommendations provided in the guidelines. For each participant, a total score will be computed across all case scenarios to determine adherence level to the latest Canadian clinical practice guideline recommendations.

Contacts

Primary ContactNellie Kamkar, MSc
Nellie.Kamkar@lhsc.on.ca1-519-661-2111 Ext. 86013
Backup ContactTina Khazaee, MSc
tina.khazaee@lhsc.on.ca1-519-661-2111 Ext. 86013

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026